Ixekizumab Linked to Low Risk of Major Cardiovascular Events in Psoriatic Patients; An analysis of patients with psoriasis, PsA, or axSpA show risk of MACE with ixekizumab is consistently low.

Press/Media

Period30 Jun 2023

Media coverage

2

Media coverage